Navigation Links
Novel drug combination offers therapeutic promise for hard-to-treat cancers
Date:9/12/2011

Boston, MA - Researchers at Brigham and Women's Hospital (BWH) have identified a new combination of targeted therapies that, together, may treat two aggressive tumor types that until now have not had effective treatments. These findings are published in Cancer Cell on September 13, 2011.

While numerous anti-cancer drugs are being developed, many tumors do not respond to currently available single therapies. As such, there is a major push to identify new drug combinations that can work together to treat these resistant cancers . The drug combination identified by BWH researchers was shown to successfully treat two models of aggressive cancers: a nervous system tumor associated with neurofibromatosis type 1, and KRAS-mutant lung cancer, a form of lung cancer that accounts for about 25 percent of all lung cancers. "Without a targeted treatment that works, these two cancers are currently being treated with chemotherapy with variable success," said Dr. Karen Cichowski, Associate Professor in Genetics at BWH and lead author of the paper. "By identifying a more effective targeted treatment, the outcome and survival rate for these cancers may see a drastic improvement, and patients may avoid the typical side-effects of chemotherapy."

Researchers took the approach of combining two targeted agents, one the mTOR inhibitor rapamycin, which suppressed tumor growth, along with the HSP90 inhibitor IPI-504 from Infinity Pharmaceuticals, which triggers a specific kind of stress in cancer cells. Together, but not alone, these drugs promoted dramatic tumor regression in these two distinct cancers in mice. "It's like hitting the tumor cell from two different angles," explains Dr. Cichowski. "Using one drug to put on the brakes and another to apply stress to an already stressed cancer cell, which ultimately triggers its self-destruction".

These studies have inspired the testing of a drug combination that is now in a Phase I clinical trial, specif
'/>"/>

Contact: Holly Brown-Ayers
hbrown-ayers@partners.org
617-534-1603
Brigham and Women's Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. Scientists identify novel inhibitor of human microRNA
2. Conaway Lab identifies novel mechanism for regulation of gene expression
3. LIAI launches new division to look at novel approaches to heart disease and inflammation
4. Childrens National researchers develop novel anti-tumor vaccine
5. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
6. Novel publishing approach puts textbook in more hands
7. GEN reports on novel tools for deciphering biological networks
8. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
9. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
10. Corn researchers discover novel gene shut-off mechanisms
11. A novel target for therapeutics against Staph infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... 2015 Today, ZTE announced its Android smartphone ... as expected revenues in 2015 that relate to sales of FPC1025 ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO ... manufacturer in China and we are proud ... 5 for Axon , its first ...
(Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... release is available in German . ... in Freiburg have gained important insights for stem cell research ... to the development of new treatments. As Rolf Kemler,s research ... determines the length of the telomeres and a signalling pathway ...
... , Akron, Ohio, June 27, 2012 Expertise in fluid ... a new research center designed to help physicians better diagnose ... neck and shoulders. Chiari malformation is a disorder of ... brain and spinal fluid. UA engineers are able to ...
... animal scientists are working together to meet the challenges of ... experimental Biology on 28th June will demonstrate innovative techniques and ... issues, crop yields and diminishing fish stocks. , In ... the world,s four most important crops has fallen short of ...
Cached Biology News:When does a headache need an engineer to fix it? 2When does a headache need an engineer to fix it? 3
(Date:7/24/2015)... Diego, CA (PRWEB) , ... July 24, 2015 , ... ... & Referral Center in support of stem cell therapy training and clinical opportunities. , ... this new opportunity to veterinarians in the San Diego area. Stem cell therapy is ...
(Date:7/24/2015)... Origin Agritech Limited (NASDAQ GS: SEED) ("Origin", or the "Company"), ... , today announced that the Company will report results ... 2015, before the market opens on Wednesday, August 5th, 2015. ... 5th, 2015, at 9:00 a.m. ET / 9:00 p.m. ... participate in the call, please dial the following numbers approximately ...
(Date:7/23/2015)... ANGELES , July 23, 2015 ImmunoCellular Therapeutics, ... to report financial results for the second quarter 2015 on ... a conference call and webcast on that day at 5:00 ... and provide a business update. The call will be hosted ...   , , , LIVE CALL: ...
(Date:7/23/2015)... , July 23, 2015 The Hong Kong ... given the prestigious accolade of "Most Innovative Technology ... world-class position in fostering innovation and technology development ... region.  The award has ... innovation and technology magazine and website with a ...
Breaking Biology Technology:VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 2HKSTP Wins Most Innovative Technology Hub at The New Economy Awards 2015 2HKSTP Wins Most Innovative Technology Hub at The New Economy Awards 2015 3
... 6 VIRxSYS Corporation announced today the publication ... Abundant Albumin Transcripts for Production of Therapeutic Proteins In ... The study describes a novel RNA therapy technique in which ... gene "hijacks" the albumin, causing it to produce the newly ...
... 6 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) ... has posted a new entry on his blog on ... recent meetings in Zurich, Switzerland, further development plans for ... for clinical-grade Oxycyte, and plans for raising additional capital. ...
... April 6 /PRNewswire/ - Orcrist Bio Inc. (ORC) ... today the approval of its Phase I, open-label, ... volunteers, by the European Competent Authority in Seville, ... assess the safety, tolerability, pharmacokinetics and pharmacodynamics (induction ...
Cached Biology Technology:VIRxSYS Publishes New Study on RNA Therapy 2Orcrist Bio Inc. Receives Approval from European Competent Authority to Initiate its Planned Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750 2
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... offers a large collection of phage ... tissuea, cell lines, and mouse tissues. ... pHD9 vector. The size of cDNA ... from 200bp to 1000bp by gel ...
... A multi-purpose, high gel-strength agarose suitable for ... from conventional constant field to Pulsed Field ... gel strength and exclusion limits, Multi ABgarose ... reduced running times. This in turn means ...
7G10 anti-Fasciclin III...
Biology Products: